Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Quick facts

Phase 3 pipeline

• Eribulin mesylate injection · Oncology
  Eribulin mesylate is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells.
• JSKN003 · Oncology
  JSKN003 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
• KN046 · Oncology
  KN046 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses.

Phase 2 pipeline

• Concurrent chemotherapy and KN026 · Oncology
  KN026 is a monoclonal antibody targeting PD-L1.
• JSKN016 injection · Oncology
  JSKN016 injection is a monoclonal antibody targeting PD-1.
• KN026 monotherapy

Phase 1 pipeline

• JSKN016 Q2W
• JSKN016 Q3W
• JSKN016HC
• JSKN022
• JSKN027

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Jiangsu Alphamab Biopharmaceuticals Co., Ltd portfolio CI brief
• Jiangsu Alphamab Biopharmaceuticals Co., Ltd pipeline updates RSS